Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 90
Healthy Volunteers: f
View:
• Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
• MMSE between 10-26
• CDR 1 or 0.5
Locations
Other Locations
Taiwan
Chang Gung Memorial Hospital
RECRUITING
Kaohsiung City
Time Frame
Start Date: 2024-06-19
Estimated Completion Date: 2027-05
Participants
Target number of participants: 80
Treatments
Experimental: Experimental
DAOIB plus Antioxidant agent (AO)
Placebo_comparator: Placebo Comparator
DAOIB plus Placebo
Related Therapeutic Areas
Sponsors
Leads: Chang Gung Memorial Hospital